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Abstract Altered hepatic cholesterol metabolism has been im- 
plicated in the etiology of cholesterol gallstones. This hypothesis 
has been examined by determining acyl-coenzyme A:cholesterol 
acyltransferase (ACAT) activity in liver biopsies from 31 cholesterol 
gallstone patients and 12 control subjects. Hepatic ACAT activi- 
ty in gallstone patients was decreased to one-third that in controls 
(P < 0.001). No differences in hepatic homogenate or microsomal 
free and total cholesterol concentrations were observed between 
the two groups. However, marked increases in free (107%) and 
total (98%) cholesterol concentrations were found in the cytosol- 
ic fraction of liver biopsies from gabtone patients. The total phos- 
pholipid concentration of the liver homogenate fraction was 
unchanged in both groups; however, the microsomal total phos- 
pholipid concentration was reduced by 17% (P < 0.01) in gall- 
stone samples compared with controls. This difference did not 
result in a significantly increased microsomal cholesterol/phos- 
pholipid ratio for the gallstone group (0.180 f 0.030) compared 
with the control group (0.169 f 0.042). These results show 
that hepatic AUT activity is significantly decreased in cholesterol 
gallstone patients. These changes in ACAT activity in livers of 
patients with cholesterol gallstones are consistent with the known 
increase in the amount of free cholesterol secreted in the bile of 
these patients. Thus, the changes in ACAT activity may contrib- 
ute to the pathogenesis of cholesterol gallstones. -Smith, J. L., 
I. R. Hardie, S. P. Pillay, and J. de Jemey. Hepatic acyl-coenzyme 
A:cholesterol acyltransferase activity is decreased in patients with 
cholesterol gallstones. J. Lzpzd Res. 1990. 31: 1993-2000. 
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In developed countries cholesterol gallstones are com- 
mon and they constitute a major health problem (1). The 
pathogenesis of cholesterol gallstones is poorly understood; 
however, it is thought to be multifactorial, with no precise 
abnormality yet identified. An essential prerequisite for 
cholesterol gallstone formation is lithogenic bile, bile su- 
persaturated with cholesterol compared with phospholipids 
and bile salts (2). The presence of nucleating factors in bile 
(3) has also been suggested. The mechanism by which litho- 
genic bile is produced in humans is not clear, but changes 
in hepatic cholesterol metabolism haw been implicated (4-14). 
Factors that influence cholesterol homeostasis in liver in- 
clude the rates of cholesterol synthesis, cholesterol esterifi- 
cation, conversion of cholesterol to bile acids, the rates of 
secretion of cholesterol into bile and plasma, the uptake 
of plasma lipoproteins, and the turnover of membrane 
cholesterol. 
The activities of cholesterol 7a-hydroxylase (EC 1.14.13.7), 
the rate-limiting enzyme for bile acid synthesis, and 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc- 
tase (EC 1.1.1.34), a rate-limiting enzyme for cholesterol 
synthesis, in liver biopsies from cholesterol gallstone pa- 
tients and controls have been determined in a number of 
studies (7-13). In five studies (7, 9, 10, 12, 13) HMG-CoA 
reductase activity was significantly increased and in one 
study (11) no change was observed. The activity of cholesterol 
7a-hydroxylase was reported to be significantly decreased 
in all studies (8-11, 13). The concentrations of cholesterol 
in the homogenate (7, 9, 12)'and microsomal (9, 11, 12) 
fractions of liver samples have also been determined for 
several groups of gallstone patients and controls with con- 
flicting results. 
Hepatic acyl-coenzyme A:cholesterol acyltransferase ( A m )  
is responsible for the intracellular esterification of choles- 
terol. There have been two reports of its activity in cholesterol 
gallstone patients (14, 15), but apart from a preliminary 
study in our laboratory (14), no systematic comparison of 
hepatic ACAT activity has been made between gallstone 
patients and controls. In this paper, we report the activi- 
ties of ACAT and the concentrations of cholesterol and to- 
tal phospholipids in liver biopsies from 31 cholesterol gallstone 
patients and 12 control subjects. 
Abbreviations: A m ,  acyl-coenzyme A:cholesterol acyltransferase; BMI, 
body mass index; CSI. cholesterol saturation index; HMG-CoA, 
3-hydroxy-3-methylglutaryl coenzyme A: LDL, low density lipoproteins; 
SD, standard deviation; VLDL, very low density lipoproteins. 
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MATERIALS AND METHODS 
Details of subjects 
The gallstone group consisted of 31 patients who were 
having elective cholecystectomy and liver biopsy for con- 
firmed gallstones at the Royal Brisbane Hospital, Brisbane, 
Australia. The control group (nongallstone) was made up 
of 12 subjects who were undergoing liver resection for cancer 
(n = 4) or who were organ donors (n = 8). The four liver 
resection patients had either metastatic colonic cancer to 
the liver, hepatocellular carcinoma, hepatic cystadenoma, 
or cavernous haemangioma. The organ donors consisted 
of subjects who died as a result of either head injuries, cerebral 
tumor, meningioma, or hypoxic brain death. Clinical data 
for each group of subjects are in Table 1. The gallstone 
and control groups wem similar except for a greater proportion 
of males in the control group. The fasting concentrations 
(mean f 1 SD) of total cholesterol and triglycerides in plasma 
from the gallstone group (n = 23) were 5.63 5~ 1.24 mM 
(range 4.10-8.70 mM) and 1.57 f 0.62 mM (range 0.68-2.63 
mM), respectively. Plasma lipid concentrations were not de- 
termined for the control subjects because of logistic difficulties 
and the problem of interpretation in the context of blood 
volume changes during resuscitation. Plasma lipids are also 
known to be altered in patients with tumors. 
Liver samples 
Liver samples were obtained with appropriate consent. 
For organ donors, consent for use of tissue for scientific 
purposes was obtained from the next of kin. For patients 
undergoing liver resection or cholecystectomy and liver bi- 
opsy, patient consent was obtained in accordance with a 
protocol approved by the hospital ethics committee. 
Patients undergoing cholecystectomy and liver biopsy were 
fasted for a minimum of 8 h prior to blood collection and 
surgery. At operation, a wedge liver biopsy (approximate- 
ly 0.7 g) was taken (usually from the left lobe) and placed 
into cold homogenizing buffer (14). Most operations oc- 
curred between 1:50 PM and 4:20 PM; three were between 
9:00 AM and 1O:OO AM (mean 2:04 PM). There was no corre- 
TABLE 1. Details of subjects 
Control Gallstone 
43.8 f 19.0 51.8 f 16.6 
(n = 12) (n = 31) 
Ma1e:female 6:6 7:24 
Weight (kg) 63.8 f 17.9 67.5 f 13.0 
(n = 4) (n = 31) 
BMI ND 25.1 f 4 . 0  
(n = 24) 
Results are given as the mean i 1 standard deviation; ND, not deter- 
mined; BMI, body mass index. 
lation between ACAT activity and the time the liver biopsy 
was taken. The biopsy was transported on ice to the laboratory 
(about 10 min) where the solution was decanted and the 
biopsy was frozen at - 70 OC. Liver samples were homogenized 
and fractions were prepared as described below. 
Control liver samples (usually 10-200 g; the majority from 
the right lobe) were taken between 2:OO AM and 10:37 PM 
(mean 12:56 PM) as previously described (16). There was 
no correlation between ACAT activity and the time the liver 
sample was taken. Liver samples were either treated the 
same as the gallstone samples as described above, rapidly 
frozen in liquid nitrogen, and stored at - 70 OC, or cut into 
small pieces and placed in a freezer kept at - 7 O O C  (16). 
Liver samples were homogenized and fractions were pre- 
pared as described below. These different treatments of the 
liver samples have been shown previously not to affect ACAT 
activity (14, 16). 
All patients (gallstone and liver resection) received similar 
anesthetic agents, whereas the organ donors (16) received 
no anesthesia. Subjects from both groups who were found to 
have metabolic abnormalities or marked histological changes 
in the liver (e.g., severe fatty changes or cirrhosis) were ex- 
cluded. Some subjects undergoing liver resection or who 
were organ donors were found to have gallstones and therefore 
were also excluded from the control group. Previously, we 
showed (16) that ACAT activity in liver from organ donors 
is similar to that in liver from liver resection cases. Thus, 
liver samples from organ donors are just as suitable as con- 
trols compared with samples from liver resection cases when 
ACAT activity is being compared. 
Preparation of liver fractions 
Liver homogenates and washed microsomes were pre- 
pared from frozen liver as described previously (17). After 
the sedimentation of microsomes, the remaining clear su- 
pernatant (cytosol) was carefully removed using a Pasteur 
pipette. All fractions were stored at - 70 OC until used for 
protein or lipid analysis or for the measurement of ACAT 
activity. Some lipid extractions were performed on liver 
homogenate and microsomes before their storage at - 7 O O C .  
ACAT activity determined in the presence of exogenous 
cholesterol is unaffected by freezing of liver tissue before 
microsomal preparation, freezing of the microsomal frac- 
tion prepared from unfrozen tissue, or freezing both the 
tissue and the subsequent microsomal fraction (14-16). Al- 
though Einarsson et al. (15) reported that either freezing 
the liver tissue or the microsomal fraction stimulated ACAT 
activity when determined in the absence of exogenous cho- 
lesterol, we found no stimulation of ACAT activity by freezing 
(14, 16). 
Assays 
ACAT activity was determined in the absence and presence 
of exogenous cholesterol (6 pg cholesterol and 150 p g  Tween 
80 per assay) using the method previously described (14, 
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16). Endogenous cholesterol in the assay was about 2.2 pg. 
In previous work (14) we found that 6 p g  of exogenous cho- 
lesterol resulted in maximal ACAT activity; higher concen- 
trations were inhibitory (14). Free and total cholesterol 
concentrations in liver fractions were measured by the method 
of Sal6 et al. (18). Plasma total cholesterol concentrations 
were determined colorimetrically using an automated 
Boehringer Mannheim cholesterol method on a COBAS- 
BIO centrifugal analyzer (Roche) in the Biochemistry Depart- 
ment of the hospital. Total phospholipids were determined 
by the method of Hess and Derr (19), modified by substituting 
Triton X-100 for Sterox, and digesting at 170 OC for 70 min 
instead of at 190°C for 25 min. A linear relationship was 
obtained between absorbance and the amount of a dipal- 
mitoyl phosphatidylcholine standard in the range 1-5 nmol 
phosphorus. Protein was estimated by the method of Lowry 
et al. (20) using bovine albumin Cohn fraction V as the 
standard protein. 
Statistical methods 
Comparisons between test and control values were as- 
sessed by the Student's t-test. Correlations between ACAT 
activity and the various lipid concentrations and patient 
characteristics were determined by linear regression. 
RESULTS 
Hepatic A U T  activities 
The mean ACAT activity of the gallstone patients was 
36% (P < 0.001) and 41% (P < 0.01) of controls when A m  
activity was determined in the prqence or absence of ex- 
ogenous cholesterol, respectively (Tkble 2). The addition of 
exogenous cholesterol to the ACAT assay stimulated ACAT 
activity by 4.3 f 2.1-fold (mean f 1 SD; range 1.3-10.6) 
in gallstone samples. In control samples the corresponding 
stimulation factor was 6.0 f 3.9 (n = 11; range 2.0-13.5). 
The difference between the effects of exogenous cholester- 
ol on ACAT activity in gallstone and control samples was 
significant at P < 0.001. 
For some control livers (n = 4) and gallstone liven (n = 8) 
ACAT activity per gram of liver tissue was determined. 
ACAT activity (mean f 1 SD) determined in the presence 
of exogenous cholesterol for samples from gallstone patients 
TABLE 2. Microsomal ACAT activity in liver biopsies from 
gallstone and control subjects 
ACAT Activity 
Sample + Cholesterol - Cholesterol 
pmol.  min-' .  mg protein-' f SD 
Control (12) 124 f 35 27 f 16 (11) 
Gallstone (31) 45 f 26 11 f 6 
P value < 0.001 < 0.01 
was 437 f 207 pmol - min-' g liver-', while the ACAT ac- 
tivity (mean f 1 SD) of control samples was 1304 f 327 
pmol - min- ' - g liver-'. This difference was statistically sig- 
nificant (P < 0.001). Similar results were found for ACAT 
activity determined in the absence of exogenous cholesterol 
(gallstone: 107 f 46 pmol- min-'. g liver-'; control: 
223 f 99 pmolsmin-'-g liver-'; P < 0.05). The total 
amount of microsomal protein recovered (mean f 1 SD) 
for the two groups was 8.82 f 2.76 mg.g liver-' for con- 
trols and 7.01 f 2.44 mg - g liver-' for those from gallstone 
patients. These recoveries were not statistically significantly 
different. Therefore, ACAT activity in gallstone patients 
was also approximately one-third that in controls when ex- 
pressed per gram of liver. 
When ACAT activities (measured in the absence or pre- 
sence of exogenous cholesterol) were compared in samples 
from different lobes of the liver from either controls or gall- 
stones samples, no significant differences were found. For 
ACAT activity determined in the presence of exogenous cho- 
lesterol the results were: control, left lobe: 145 f 37 
pmol.min-'.mg-' (n = 4), right lobe: 121 f 25 
pmol.min-'.mg-' (n = 7); gallstone, left lobe: 58 f 20 
pmol.min-'.mg-' (n = 9), right lobe: 60 f 17 
pmol- min-' mg-' (n = 6). A similar pattern of results 
was found for ACAT activity determined in the absence 
of exogenous cholesterol. 
Hepatic cholesterol and total phospholipid mncentrations 
There were no significant differences in homogenate or 
microsomal free and total cholesterol concentrations be- 
tween the control and gallstone groups (Thble 3). However, 
compared with the controls, the gallstone samples showed 
a 107% (P < 0.001) and a 98% (P < 0.001) incwase in cyto- 
solic concentrations of free and total cholesterol respectively. 
Cytosolic cholesteryl ester concentrations were not signifi- 
cantly different between the two groups, although they tended 
to be higher in samples from patients with cholesterol 
gallstones. 
There wem no significant differences in total phospholipid 
concentrations in homogenate fractions from control and 
gallstone samples. However, the microsomal fraction of the 
gallstone group showed a 17% (P < 0.01) decrease com- 
pared with the control group. Phospholipids were not de- 
tected in the cytosolic fractions from either group. The 
cholesterol/phospholipid ratio for the microsomal samples 
was 0.180 f 0.030 for the gallstone group (n = 24) and 
0.169 f 0.042 for the control group (n = 11). This differ- 
ence was not statistically significant. 
Correlations between A U T  activity and hepatic 
lipid concentrations 
When ACAT activity in control samples was determined 
in the absence of exogenous cholesterol it was positively cor- 
related with microsomal free cholesterol concentration 
(Fig. 1A; P < 0.035), with cytosolic free cholesterol con- 
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TABLE 3. Concentrations of cholesterol and phospholipids in various fractions of liver from gallstone and control subjects 
Homogenate Microsomal Cytosolic 
TC FC PL Tc FC PL Tc FC CE 
nmol. mg protein-’ ~t SD 
(n = 9) (n = 10) (n = 10) (n = 10) (n = 11) (n = 11) (n = 11) (n = 11) (n = 9) 
Control 41.8 f 12.4 40.9 f 12.4 183 f 23 95.2 * 24.1 93.9 f 21.8 563 f 82 5.80 f 4.22 3.87 f 3.02 2.37 f 1.13 
Gallstone 45.3 f 7.1 40.8 * 7.0 188 f 29 90.8 f 22.7 89.5 5 21.9 469 f 105 11.46 f 3.56 8.02 f 3.25 3.59 f 1.19 
(n = 26) (n = 24) (n = 26) (n = 29) (n = 24) (n = 29) (n = 26) (n = 29) (n = 26) 
P value NS NS NS NS NS < 0.01 < 0.001 < 0.001 NS 
TC, total cholesterol; FC, free cholesterol; PL, total phospholipid; CE, cholesteryl esters; NS, not significant. 
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In contrast, for samples from gallstone patients, ACAT 
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ples, A U T  activity was positively correlated with homoge- 
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Fig. 1. Correlations between hepatic ACAT activity and hepatic lipid concentrations in control subjects. ACAT activity determined in the absence 
of exogenous cholesterol (- cholesterol) and presence of exogenous cholesterol (+ cholesterol). (A) Microsomal free cholesterol, n = 11, r = 0.637. 
P < 0.035, y = 0 . 4 5 ~  - 15.8. (B) Cytosolic free cholesterol, n = 11, T = 0.627, P < 0.04, y = 3 . 2 2 ~  + 14.4. (C) Microsomal total phospholipid, n = 11. 
T = 0.682, P < 0.021, y = 0 . 3 1 ~  - 50.2. (D) Cytosolic cholesteryl ester, n = 9,  t = 0.613, P < 0.028, y = 7 . 6 2 ~  + 10.4. 
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Fig. 2. Correlations between hepatic ACAT activity and hepatic lipid concentrations in gallstone patients. ACAT activity determined in the absence 
of exogenous cholesterol (- cholesterol) and presence of exogenous cholesterol (+ cholesterol). (A) Microsomal free cholesterol, n = 24, r = 0.454, 
P < 0.026, y = 0 . 5 3 ~  - 0.63. (B) Cytosolic free cholesterol, n = 29, r = 0.381, P < 0.041, y = 67.6 - 3 . 0 9 ~ .  (C) Microsomal total phospholipid, 
n = 29, r = 0.508, P < 0.005, y = 0 . 1 3 ~  - 17.1. (D) Cytosolic total cholesterol, n = 26, r = 0.424, P < 0.031, y = 81.3 - 3 . 2 2 ~ .  
correlation with microsomal free cholesterol or cytosolic 
cholesteryl ester concentrations. 
When ACAT activity in samples from gallstone patients 
was determined in the presence of exogenous cholesterol, 
a positive correlation between ACAT activity and micro- 
somal free cholesterol concentration (Fig. 2A; P < 0.026) 
was observed. Negative correlations between ACAT activity 
and cytosolic free (P < 0.041) and total (P < 0.031,) choles- 
terol concentrations (Figs. 2B and 2D) were found. Again, 
similar to the control samples a positive correlation was 
found between ACAT activity and microsomal total phos- 
pholipid concentration (Fig. 2C; P < 0.005). 
Correlations between A U T  activity and patient 
characteristics 
No significant correlation of ACAT activity (determined 
in the absence and presence of exogenous cholesterol) with 
age was found for the controls. Insufficient data on the sub- 
jects' weight and body mas index (BMI) did not allow mean- 
ingful correlations to be made on these variables. No 
statistically significant difference in ACAT activity was found 
between male and female control subjects. 
Regression analyses of the variations of ACAT activity 
(determined in the absence and presence of exogenous cho- 
lesterol) with age, weight, BMI, and plasma total cholesterol 
concentrations for the gallstone patients showed no corre- 
lations. Also, as for controls, no statistically significant differ- 
ence was found between male and female gallstone patients. 
DISCUSSION 
The present results demonstrate that there is a two- to 
three-fold decrease in hepatic ACAT activity in cholester- 
ol gallstone patients (Table 2), confirming and extending 
our previously reported results on a small number of pa- 
tients (14). This difference was apparent whether ACAT 
activity was determined in the absence or presence of ex- 
ogenous cholested or whether e x p r e s s e d  relative to microsomal 
protein (Table 2) or per gram liver. This lower ACAT ac- 
tivity and d u c e d  stimulation of ACAT activity by exogenous 
cholesterol in samples from gallstone patients suggest that 
these samples may have had less active ACAT protein or 
less ACAT protein compared with control samples. 
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Comparison of hepatic A U T  activity and patient charac- 
teristics suggest that hepatic ACAT activity is independent 
of age, sex, weight, BMI, plasma total cholesterol concen- 
tration, and the site of the liver biopsy (either the left or 
the right lobe). 
No changes in free or total cholesterol concentrations 
were observed in the homogenate or the microsomal frac- 
tion of the liver samples from gallstone patients and con- 
trols (Table 3). These findings are in agreement with one 
report (12), but not others (7, 9, 11). It should be noted 
that the number of subjects in the present study is larger 
than that in the other studies (7, 9, 12); in the study by 
Carulli et al. (ll), only microsomal free cholesterol con- 
centration was determined. 
In the present study, liver cytosolic free and total cholesterol 
concentrations werc increased in the gallstone samples com- 
pared with the control samples (Table 3). Cytosolic cholesterol 
concentrations have not previously been reported in liver 
from gallstone patients or controls. The difference suggests 
that this component may be of importance in the etiology 
of cholesterol gallstones and may reflect, in part, the en- 
zymatic changes that occur in hepatic cholesterol metabolism 
of gallstone patients (7-13). 
Reduced ACAT activity, as reported in this study, cou- 
pled to an increase in activity of HMG-CoA reductase and 
cholesterol synthesis and a decrease in the activity of cho- 
lesterol 7a-hydroxylase may lead to an increase in intra- 
cellular free cholesterol. The increased cytosolic cholesterol 
level found in the liver of gallstone samples may reflect this 
and be evidence of an altered precursor pool of free cholesterol 
destined for secretion into bile and/or plasma lipoproteins 
in these patients. Patients with cholesterol gallstones are 
well known to have an increased biliary output of cholesterol 
(21) and a positive correlation was reported between choles- 
terol saturation index (CSI) of gallbladder bile and plas- 
ma VLDL-cholesterol in cholesterol gallstone patients (22). 
A similar correlation between levels of plasma LDL (the 
major product of VLDL degradation) and bile CSI has been 
shown in normal subjects (23). The mechanism of direc- 
tion of cholesterol into the biliary and lipoprotein path- 
ways is not known: however, it may involve a cytosolic sterol 
carrier protein such as SCP2 (24, 25). 
Although a slight decrease in microsomal total phospho- 
lipid concentration was observed in liver samples from gall- 
stone patients, no differences in the microsomal cholesterol/ 
phospholipid ratio or in the microsomal cholesterol con- 
centration were detected between galltone and control samples. 
This may indicate that the lower ACAT activity in gallstone 
patients is not due to a net change in the microsomal lipid 
concentration or composition. However, since alterations 
in membrane lipid composition are reported to correlate 
with changes in ACAT and HMG-CoA reductase activities 
(26-31), further analyses of the microsomal lipids are re- 
quired to exclude this possibility. However, ACAT activi- 
ties can vary with microsomal lipid concentration within 
both the control and gallstone patient groups (Figs. 1 and 2). 
Based on our data, a more likely explanation for the re- 
duced hepatic ACAT activity observed in gallstone patients 
is that a lower amount of enzyme is present compared with 
controls. This notion is supported by our finding that hepatic 
ACAT activity is reduced in gallstone patients compared 
with controls regardless of whether the enzyme is assayed 
with exogenous cholesterol under apparent V,, conditions 
or whether the activity is assayed using the endogenous cho- 
lesterol as substrate. 
Animal studies have shown that changes in hepatic choles- 
terol metabolism can result in a change in bilialy cholesterol 
concentration or a change in the origin of biliary cholesterol. 
Chronic administration of progesterone (an inhibitor of 
ACAT) increased biliary cholesterol secretion in the rat (5). 
Turley and Dietschy (32) found that the origin of biliary 
cholesterol could be altered by stimulating or decreasing 
cholesterol synthesis in rats. Stone et al. (4) found that acute 
changes in rat hepatic enzyme activities produced acute 
changes in biliary cholesterol concentration and/or in the 
origin of biliary cholesterol. The relevance of these animal 
models to humans is unclear; however, they do show that 
the net effect of alterations of hepatic enzymes of cholesterol 
metabolism may be to alter secretion of biliary cholesterol. 
The difficulty of in vivo manipulations in humans leaves 
uncertainty about the relationship between hepatic choles- 
terol metabolism and regulation of biliary cholesterol secre- 
tion in man. Maton, Reuben, and Dowling (33) found no 
correlation between HMG-CaA reductase activity and choles- 
terol secretion, whereas Key et al. (13) found a direct correla- 
tion between HMG-CoA reductase activity and cholesterol 
secretion. Recently, Duane et al. (6) demonstrated in hu- 
mans that treatment with simvastatin, an inhibitor of HMG- 
CoA reductase, resulted in 24% reduction in the biliary 
cholesterol saturation index of gallbladder bile. Addition- 
al studies in humans are required to elucidate the roles of 
enzymes of hepatic cholesterol metabolism in regulating 
biliary cholesterol secretion. 
This study demonstrates that hepatic ACAT activity is 
significantly decreased in cholesterol gallstone patients. This 
decrease in ACAT activity, together with earlier reports of 
increases in hepatic HMG-CoA reductase and decreases in 
cholesterol 7a -hydroxylase activities in gallstone patients, 
suggests that the net effect of these changes is to increase 
the availability of free cholesterol within the hepatocyte for 
efflux into the bile. These results further support the hypo- 
thesis that an altered hepatic cholesterol metabolism is in- 
volved in the etiology of cholesterol gallstones. 1(1111 
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